… favorable outcomes, metastatic prostate cancer is currently … prostate cancer with ten
new drugs approved in the United States for metastatic castration resistant prostate cancer (mCRPC) …

4508^ Background: The treatment of mCRPC following docetaxel (D) therapy failure due to
progressive disease (PD) or toxicity is an unmet medical need. TROPIC evaluated the …

4516 Background: Cabozantinib (Cabo) is an inhibitor of MET and VEGFR2. MET signaling
promotes tumor growth, invasion and metastasis. Methods: mCRPC patients (pts) with …

… mCRPC who received up to three lines of therapy. 23% of patients did not receive a life-prolonging
therapy after the initial diagnosis of mCRPC… the diagnosis of mCRPC was 21 months. …

… Eligible patients had to be diagnosed with prostate cancer (defined as histologic confirmation
of prostate cancer or as concluded by the treating doctor based on elevated PSA and …

… advanced prostate cancer treated with androgen deprivation therapy experience relapse
with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC) 1 . …

… of metastatic castration-resistant prostate cancer (mCRPC) that showed an increase in …
, and radium-223) have received regulatory approval for mCRPC in the United States (US). …

Background Loss-of-function alterations in HRR genes are associated with response to
PARP inhibition. PROfound (NCT02987543) is a randomized, open-label, phase III trial …

… as a component of a true response biomarker for mCRPC. Here, we used the bone scan index
(BSI… Methods: mCRPC patients (pts) from clinical trials using PCWG2 criteria to determine …

Background Effective therapies for pts with treatment-refractory mCRPC are an important
unmet medical need. Niraparib is a highly selective poly ADP-ribose polymerase (PARP) …